血脂康对早期糖尿病肾病患者氧化应激的影响

Effect of Xuezhikang on Oxidative Stress in Early Diabetic Nephropathy

目的探讨血脂康对早期糖尿病肾病(DN)患者氧化应激的影响。方法将56例早期DN患者随机分成血脂康组(28例)和安慰剂组(28例),另外选20例健康体检者作为正常对照组。DN患者均给予胰岛素控制血糖,血脂康组加用血脂康0.6 g/次,3次/d;安慰剂组加用外形相同含淀粉的胶囊,0.6 g/次,3次/d,均治疗12周。治疗前后观察3组受试者血脂〔三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、极低密度脂蛋白胆固醇(VLDL-C)、高密度脂蛋白胆固醇(HDL-C)〕水平及血清丙二醛(MDA)、超氧化物歧化酶(SOD)、尿清蛋白排泄率(UAER)的变化。结果与正常对照组比较,血脂康组和安慰剂组早期DN患者TG、TC、LDL-C、VLDL-C水平显著升高,HDL-C水平显著降低,血清SOD显著下降,MDA水平上升(P<0.05);血脂康治疗12周后,患者血清TG、TC、LDL-C、VLDL-C、MDA水平及UAER较治疗前显著下降,HDL-C水平及血清SOD活性较治疗前显著上升(P<0.05)。安慰剂处理前、后患者血脂、血清SOD、MDA及UAER间差异无统计学意义(P>0.05)。结论早期DN患者存在血脂紊乱和氧化应激,血脂康可调节早期DN患者血脂紊乱,并改善氧化应激,降低UAER,对早期DN治疗有益。

Objective To study the effect of Xuezhikang on oxidative stress in patients with early diabetic nephropathy （DN） . Methods 56 patients with early DN were randomly divided into Xuezhikang group （ n = 28 ） and placebo group （ n = 28） . Besides, 20 healthy physical examination people were selected as control group. Insulin was used in all pa- tients. Xuezhikang group was given Xuezhikang 0. 6 g each time and tid for 12 weeks. Placebo group was given starch capsule in the same shape of Xuezhikang 0. 6 g each time and rid for 1：2 weeks. The levels of blood lipid （ including TG, TC, LDL - C, VLDL - C, and HDL - C） , SOD, MDA and UAER were observed in the three groups before and after treatment respective- ly. Results Compared with control group, TG, TC, LDL - C, VLDL - C and MDA of early DN patients were significantly in- creased, while HDL- C and SOD were significantly decreased （P 〈0.05） . In Xuezhikang group, after 12 weeks treatment, TG, TC, LDL- C, VLDL - C, MDA and UAER were significantly decreased and HDL - C and SOD were significantly in- creased compared with those before treatment （ P 〈 0. 05 ） . After the treatment of placebo, serum levels of lipid profile, serum SOD, MDA and UAER showed no statistically difference compared with those before the treatment （ P 〉 0.05 ） . Conclusion Patients with early DN are usually with dyslipidemia and oxidative stress. Xuezhikang is conducive to the treatment of early DN through regulating blood lipid disorders, improving oxidative stress and reducing UAER.